AKT1 is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT2 is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT3 is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

CRKL is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains CRKL status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

KIT is altered in 37.5% of systemic mastocytosis with an associated hematological neoplasm (SM-AHN) patients [2].

KIT is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains KIT status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

MTOR is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains MTOR status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA is an inclusion eligibility criterion in 2 clinical trials for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 2 are open and 0 are closed. Of the trials that contain PDGFRA status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 2 are phase 1 (2 open) [3].

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains PTEN status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

RICTOR is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

RPTOR is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC1 is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC2 is an inclusion eligibility criterion in 1 clinical trial for systemic mastocytosis with an associated hematological neoplasm (SM-AHN), of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and systemic mastocytosis with an associated hematological neoplasm (SM-AHN) as inclusion criteria, 1 is phase 1 (1 open) [3].